2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, White Blood Cell Disorders, Infectious Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

2247 Etentamig with step-up dosing in patients with relapsed/refractory multiple myeloma (RRMM): Long-term (>2-year) follow-up safety and efficacy results from Arm A of the Phase 1b MONVISO study

Muhamed Baljevic, Director, Multiple Myeloma Program, Director, Vanderbilt Amyloidosis Multidisciplinary Program (VAMP), Hira Mian, MD2, Hila Magen3, Moshe Gatt, MD4, Irit Avivi Mazza, MD5, Emma Searle, MBChB, PhD6, Eben Lichtman7, John McKay, DO8, Saurabh Chhabra, MD, MBBS9, Sarah Leeth Farmer10, Neha Korde, MD11, Hana Safah, MD12, Iuliana Vaxman13, Jovian Yu, MD, MS, MBA14, Anders Svensson, MD15, Thomas Doerr, MSc16, Priya Malini17, David M. Hoffman18, Shane Lee19, Tanya S. Rosenberg, MD20, Akshanth R. Polepally, PhD21, Sneha Rathi, PhD22, Aarif Ahsan, PhD23, Shaji Kumar, MD24
1 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
2 McMaster University, Hamilton, Ontario, Canada
3 Hematology Chaim Sheba Medical Center, Ramat-Gan, Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
4 Department of Hematology, Hadassah Medical Center and Hebrew University of Jerusalem, Jerusalem, Israel
5 Department of Hematology, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel
6 The Christie NHS Foundation Trust, Manchester, United Kingdom
7 UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
8 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
9 Mayo Clinic Arizona, Phoenix, Arizona, United States
10 Vejle Hospital and University of Southern Denmark, Vejle, Denmark
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana, United States
13 Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel, Institute of Haematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikvah, Israel
14 AbbVie Inc., North Chicago, Illinois, United States
15 AbbVie Inc., North Chicago, Illinois, United States
16 AbbVie Inc., North Chicago, Illinois, United States
17 AbbVie Inc., North Chicago, Illinois, United States
18 AbbVie Inc., North Chicago, Illinois, United States
19 AbbVie Inc., North Chicago, Illinois, United States
20 AbbVie Inc., North Chicago, Illinois, United States
21 AbbVie Inc., North Chicago, Illinois, United States
22 AbbVie Inc., North Chicago, Illinois, United States
23 AbbVie Inc., North Chicago, Illinois, United States
24 Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States

Introduction: Etentamig is being developed as a next-generation differentiated B-cell maturation antigen (BCMA) x CD3 bispecific T-cell engager, optimized for convenient monthly (Q4W) dosing from the start, and composed of a bivalent BCMA-binding domain with high avidity, and a low-affinity CD3-binding domain potentially reducing both cytokine release syndrome (CRS) and infection rates. Previous results from Arm A of the phase 1b MONVISO study of etentamig monotherapy in patients (pts) with RRMM showed robust efficacy and a favorable safety profile, including low rates of CRS and infections. Here we present long-term follow-up safety and efficacy data from Arm A of MONVISO, evaluating etentamig with step-up dosing (SUD) to mitigate frequency and severity of CRS in pts with RRMM.

Methods: Arm A of the multicenter, open-label, phase 1b MONVISO study (NCT05650632) evaluated etentamig monotherapy in adults (aged ≥18 years) with RRMM who have received ≥3 prior lines of therapy (pLoT), including triple-class exposure (≥1 proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody). Pts had an Eastern Cooperative Oncology Group performance score (ECOG-PS) of ≤2 and no prior BCMA-targeted therapy exposure. During dose optimization (DO), pts received etentamig intravenous (IV) with SUD (2 or 4 mg) on Cycle 1 Day 1 followed by 60 mg on Cycle 1 Day 4 and Q4W thereafter. During dose expansion (DE), pts received etentamig IV 2 mg SUD on Cycle 1 Day 1 followed by 60 mg IV on Cycle 1 Day 4 and Q4W thereafter. Primary and secondary safety endpoints were Grade (G) ≥2 CRS events during Cycle 1 and any grade CRS events, respectively. Exploratory efficacy endpoints included overall response rate (ORR), duration of response (DoR), progression-free survival (PFS), and minimal residual disease (MRD)-negativity rate (defined as bone marrow aspirate at a threshold of 10−5 as measured by next-generation sequencing).

Results: At data cutoff (March 31, 2026), 70 pts had been treated; in DO, 26 and 21 were treated with 2 and 4 mg SUD, respectively, and 23 pts in DE were treated with 2 mg SUD. Of all pts, 41 (58.6%) were male, 56 (81.2%) were White, and median (range, depicted onward) age was 69 (40–84) years. The median number of pLoT was 4 (3–11), 68 (97.1%) pts had ECOG-PS ≤1, and 53 (75.7%) were triple-class refractory. Hypogammaglobulinemia at baseline, defined as corrected (adjusted for monoclonal M protein) immunoglobulin G ≤400 mg/dL was observed in 32 (45.7%) pts. After a median follow up of 25.4 (0.8–35.3) months, ORR (95% confidence interval [CI]) was achieved by 49 (70.0% [58.8%–81.3%]) pts with median time to first objective response of 1.1 (1.0–4.0) months. Median (95% CI) DoR and PFS were 27.2 (17.3–not estimable) and 16.6 (8.7–29.3) months, respectively. Among MRD-evaluable pts achieving ≥ complete response (n=23), 21 (91.3%) were MRD-negative. Of all treated pts (N=70), 47 (67.1%) discontinued treatment, primarily due to progressive disease (n=36 [51.4%]) or adverse events (AEs; n=6 [8.6%]). Deaths due to AEs occurred in 6 (8.6%) pts with only 1 (1.4%) death (COVID-19 pneumonia) considered possibly related to etentamig; at the time of death, the pt was hypogammaglobulinemic and had not received immunoglobulin prophylaxis. No pts received prophylactic tocilizumab for CRS. With 2 mg SUD in DE (n=23), CRS was reported in 7 (30.4%) pts and was primarily low grade (G1: 26.1%; G2: 4.3%; G≥3: 0%). Median times to onset and resolution of CRS were 22.3 (5.5–29.6) and 20.7 (1.8–131.7) hours, respectively, with no cases (0%) of recurrence. Immune effector cell-associated neurotoxicity syndrome was reported in 3 (13.0%) pts with no G3 or higher events; all events resolved, with 1 (4.3%) case of recurrence. Of all pts (N=70), 22 (31.4%) experienced G3/4 infection, with pneumonia (n=11 [15.7%]) being the most common. Sixty (85.7%) pts experienced hypogammaglobulinemia; immunoglobulin replacement was administered to 35 (50.0%) pts. G3/4 neutropenia, anemia, and thrombocytopenia were reported in 35 (50.0%), 14 (20.0%), and 7 (10.0%) pts, respectively.

Conclusions: After long-term follow-up of >2 years, etentamig treatment led to deep and durable responses in heavily pretreated pts with RRMM. Alongside SUD and a modified premedication schedule, even with extended follow-up etentamig demonstrates a favorable safety profile, with low rates of CRS and G3/4 infection.

Muhamed Baljevic, Director, Multiple Myeloma Program, Director, Vanderbilt Amyloidosis Multidisciplinary Program (VAMP): National Comprehensive Cancer Network - Honoraria; Targeted Oncology - Honoraria; Curio Science - Honoraria; MJH Life Sciences - Honoraria; Johnson & Johnson - Research Funding; Pfizer - Research Funding; Sanofi-Genzyme - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Parexel - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Delta-Fly Pharma - Consultancy (Includes expert testimony); Prothena - Consultancy (Includes expert testimony); Cardinal Health - Consultancy (Includes expert testimony); Karyopharm Therapeutics - Consultancy (Includes expert testimony); Janssen Research and Development - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Xilis Inc. - Consultancy (Includes expert testimony); Legend Biotech - Consultancy (Includes expert testimony); Bristol Myers Squibb/Celgene - Consultancy (Includes expert testimony)